

Cancer Drugs Fund notification numbers by drug and indication: reporting period Apr-17 to Mar-18

A. Summary

The Cancer Drugs Fund (CDF) is a source of funding for cancer drugs in England. On 29 July 2016, the approach to the appraisal and funding of cancer drugs in England was reformed and a new CDF introduced, which provides earlier access to cancer drugs than before. The NICE appraisal process starts much earlier, to enable final guidance to be published soon after a drug has received its license. In addition, all cancer drugs recommended for either routine commissioning or CDF managed access arrangements are funded from the draft positive recommendation from NICE – i.e. publication of the Final Appraisal Document (FAD) – thus providing patients earlier access to new treatments. If a cancer drug is given a positive recommendation, the CDF will fund this treatment until 90 days after NICE have published final guidance - after which, it will be funded through routine commissioning.

The information below sets out the number of patients notified to the CDF, broken down by month for each cancer treatment. Please note that notifications reflect the number of patients registered to receive treatment through the CDF: this may not represent the number of these patients who actually went on to receive treatment. Notifications to use drugs that have moved into routine commissioning are not reflected in the table below.

In the period Apr-17 to Mar-18 the CDF received:

4163	patient notifications for transition drugs ¹
2663	patient notifications for drugs receiving interim CDF funding ²
3694	patient notifications for drugs receiving CDF funding via a managed access agreement (MAA) ³
21	patient notifications received for drugs that have since been removed from the CDF

Making a total of

10541	patient notifications overall
--------------	-------------------------------

Notes:

- 1 In 2017/18 the CDF was continuing to fund drugs from the old CDF (pre-July 2016) until they were re-appraised by the National Institute for Health and Care Excellence (NICE) or NHS England (in the case of the off-label drug indications).
- 2 All newly recommended cancer drugs receive interim CDF funding giving patients access to these treatments many months earlier than before.
- 3 CDF managed access agreements (MAA) provide funding for treatments that show clinical promise, but for which further data collection is needed in order to resolve uncertainty around their effectiveness.

B. Report by drug and indication

Please note: where notification numbers are low and therefore risk potentially identifying patients, the monthly and annual figures have been suppressed.

Blueteq Form ref:	Drug	Indication	Date CDF funding began	Date transferred into routine commissioning	Apr-17	May-17	Jun-17	Jul-17	Aug-17	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Suppressed total	
ATE1	Atezolizumab	The first line treatment of locally advanced or metastatic urothelial cancer in patients who are ineligible for cisplatin-based chemotherapy	01 November 2017	nca								<10	13	15	21	25	<100	
AVE1	Avelumab	The treatment of previously untreated (with systemic therapy) metastatic Merkel cell carcinoma	01 March 2018	nca													<10	<10
AVE2	Avelumab	The treatment of previously treated (with systemic cytotoxic chemotherapy) metastatic Merkel cell carcinoma	01 March 2018	10 July 2018													<10	<10
BEN1	Bendamustine	The first line treatment of low grade lymphoma	29 July 2016	06 July 2018	51	69	74	74	65	66	83	76	53	73	65	64	813	
BEN2	Bendamustine	The first line treatment of mantle cell non-Hodgkin's lymphoma	29 July 2016	06 July 2018	<10	<10	<10	<10	10	11	10	12	<10	<10	<10	10	<100	
BEN5	Bendamustine	The treatment of relapsed multiple myeloma	29 July 2016	nca	<10	<10	11	11	<10	16	<10	14	12	10	<10	<10	<200	
BEN6	Bendamustine	The treatment of relapsed low grade lymphoma	29 July 2016	nca	26	31	34	33	33	30	33	35	29	31	27	27	369	
BEV2	Bevacizumab	The first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy	29 July 2016	nca	15	13	21	17	16	17	10	15	11	25	14	19	193	

Blueteq Form ref:	Drug	Indication	Date CDF funding began	Date transferred into routine commissioning	Apr-17	May-17	Jun-17	Jul-17	Aug-17	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Suppressed total	
BEV3	Bevacizumab	The first line treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer	29 July 2016	nca	54	78	78	68	73	57	77	79	52	101	53	71	841	
BEV8	Bevacizumab	The third line treatment of low grade gliomas of childhood	29 July 2016	nca	<10	<10	<10	<10	0	0	<10	<10	<10	<10	<10	<10	<50	
BLI1	Blinatumomab	The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in ADULT patients	27 April 2017	26 September 2017	0	<10	<10	<10	<10	<10							<50	
BLI2	Blinatumomab	The treatment of relapsed/refractory Philadelphia negative B-precursor acute lymphoblastic leukaemia in CHILD patients	27 April 2017	26 September 2017	0	0	0	<10	<10	<10							<10	
BOR1	Bortezomib	The treatment of bortezomib naive relapsed multiple myeloma	29 July 2016	nca	<10	10	<10	10	<10	11	<10	<10	<10	<10	<10	<10	<100	
BRE1	Brentuximab	The treatment of refractory systemic anaplastic lymphoma	29 July 2016	02 January 2018	<10	<10	<10	<10	<10	<10	0	0	0	0			29	
BRE2	Brentuximab	The treatment of relapsed or refractory CD30+ Hodgkin's lymphoma	29 July 2016	02 May 2017	13	0									13			
BRE3	Brentuximab	Treatment of brentuximab-naive relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant in ADULT patients	02 May 2017	26 September 2017			<10	<10	0	<10							<20	
BRE5	Brentuximab	Treatment of brentuximab-naive relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option in ADULT patients	02 May 2017	11 September 2018			12	18	13	18	16	14	12	<10	11	<10	<10	<200
BRE6	Brentuximab	Treatment of brentuximab-naive relapsed/refractory Hodgkin lymphoma following at least 2 prior therapies when autologous stem cell transplant or multi-agent chemotherapy is not a treatment option in CHILD patients	02 May 2017	11 September 2018			0	0	<10	0	0	<10	0	0	0	0	0	<10
BRE7	Brentuximab	Re-use of brentuximab in relapsed/refractory Hodgkin lymphoma in ADULT patients	29 July 2016	26 September 2017	0	0	0	<10	<10	0							<10	
BRE9	Brentuximab	The treatment of relapsed or refractory systemic anaplastic large cell lymphoma in ADULT patients	29 July 2016	02 January 2018	0	0	0	0	<10	<10	<10	<10	<10	<10			20	
BRE10	Brentuximab	The treatment of relapsed or refractory systemic anaplastic large cell lymphoma in CHILD patients	29 July 2016	02 January 2018	0	0	0	0	0	0	<10	0	0	0			<10	
CABO1	Cabozantinib	The treatment of medullary thyroid cancer	29 July 2016	26 June 2018	0	<10	<10	<10	0	0	<10	<10	0	0	<10	<10	<50	
CABO2	Cabozantinib	The treatment of renal cell carcinoma	10 July 2017	08 November 2017				22	37	44	35	<10					<200	
CAR1	Carfilzomib	The treatment of previously treated multiple myeloma	09 June 2017	17 October 2017			<10	11	10	13	<10						<50	
CER2	Ceritinib	The first line treatment of anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer	07 December 2017	24 April 2018								0	<10	<10	0	<10	<10	
CET1	Cetuximab	The treatment of previously untreated metastatic colorectal cancer	29 July 2016	27 June 2017	63	101	90											254
CET4	Cetuximab	The treatment of previously untreated metastatic colorectal cancer	29 July 2016	27 June 2017	26	28	31											85
CET7	Cetuximab	The first line treatment of recurrent/metastatic head and neck but not oral cavity cancer	29 July 2016	30 October 2017	21	23	27	34	30	17	16						168	
CLO1	Clofarabine	The treatment of relapsed/refractory acute lymphoblastic leukaemia	29 July 2016	nca	<10	0	0	<10	<10	0	<10	0	<10	0	<10	<10	<50	
CLO2	Clofarabine	The treatment of relapsed/refractory acute myeloblastic leukaemia	29 July 2016	n/a	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<100	
DAR1	Daratumumab	The treating relapsed and refractory multiple myeloma	17 January 2018	nca											36	79	108	223
EVE3	Everolimus	The treatment of metastatic renal cell carcinoma	29 July 2016	23 May 2017	<10	<10											<10	
EVE6	Everolimus	The treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression	12 May 2017	26 September 2017			<10	<10	<10	<10	<10						<50	
EVE7	Everolimus	The treatment of unresectable or metastatic neuroendocrine tumours of gastrointestinal or lung origin with disease progression	12 May 2017	26 September 2017			<10	<10	17	<10	10						<50	

Blueteq Form ref:	Drug	Indication	Date CDF funding began	Date transferred into routine commissioning	Apr-17	May-17	Jun-17	Jul-17	Aug-17	Sep-17	Oct-17	Nov-17	Dec-17	Jan-18	Feb-18	Mar-18	Suppressed total	
PEMB2	Pembrolizumab	The treatment of untreated PD-L1 positive metastatic non-small-cell lung cancer	31 May 2017	16 October 2018	0	<10	205	157	151	140	161	153	141	181	148	175	1618	
PEMB3	Pembrolizumab	Pembrolizumab for locally advanced or metastatic urothelial cancer previously treated with platinum-based chemotherapy	16 March 2018	nca												38	38	
PER1	Pertuzumab	The first line treatment of locally advanced or metastatic breast cancer	29 July 2016	05 June 2018	63	74	89	59	79	64	69	72	50	82	62	73	836	
PLD1	Pegylated Liposomal Doxorubicin	The treatment of sarcomas	29 July 2016	nca	<10	<10	<10	<10	<10	<10	<10	<10	0	<10	<10	<10	<50	
POM1	Pomalidomide	The treatment, with dexamethasone, of relapsed and refractory multiple myeloma after at least three regimens including lenalidomide and bortezomib	23 November 2016	11 April 2017	20												20	
PON1	Ponatinib	The treatment of Philadelphia chromosome positive acute lymphoblastic leukaemia	29 July 2016	26 September 2017	<10	<10	<10	<10	<10	<10							<50	
PON5	Ponatinib	The treatment of chronic phase, accelerated phase or blast phase chronic myeloid leukaemia	29 July 2016	26 September 2017	0	<10	<10	<10	<10	<10							<50	
REG1	Regorafenib	Treatment of adult patients with advanced gastrointestinal stromal tumours (GIST) after failure of at least previous imatinib and sunitinib	29 July 2016	14 February 2018	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10		<50	
RIB1	Ribociclib (in combination with an aromatase inhibitor)	The treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer	16 November 2017	20 March 2018								<10	12	11	19	18	<100	
SOR1	Sorafenib	The first line treatment of advanced hepatocellular carcinoma	29 July 2016	06 September 2017	43	41	56	39	51	44							274	
SOR2	Sorafenib	The treatment of differentiated thyroid cancer after radioactive iodine	29 July 2016	06 November 2018	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<100	
SOR3	Sorafenib	The first line treatment of Child-Pugh A locally advanced or metastatic hepatocellular carcinoma	29 July 2016	05 December 2017	0	0	0	0	0	<10	40	49	<10				<200	
SOR4	Sorafenib	The first line treatment of Child-Pugh B locally advanced or metastatic hepatocellular carcinoma	10 August 2017	05 November 2017					0	0	<10	0						<10
SUN1	Sunitinib	The treatment of unresectable or metastatic neuroendocrine tumours of pancreatic origin with disease progression	29 July 2016	26 September 2017	<10	<10	<10	<10	<10	<10							<50	
TIV1	Tivozanib	The treatment of advanced renal cell carcinoma	12 February 2018	19 June 2018												<10	<10	<10
TRA1	Trastuzumab Emtansine	The treatment of HER2-positive locally advanced/unresectable or metastatic (Stage IV) breast cancer	29 July 2016	17 October 2017	32	39	47	41	39	41	42							281
VAN1	Vandetanib	The first line treatment of medullary thyroid cancer	29 July 2016	n/a	0	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<10	<50	
VEN1	Venetoclax	Treatment of chronic lymphatic leukaemia in the ABSENCE of 17p deletion (and absence of TP53 mutation if tested)	05 October 2017	nca							32	24	<10	13	<10	<10	<100	
VEN2	Venetoclax	The treatment of chronic lymphatic leukaemia in the PRESENCE of 17p deletion or TP53 mutation	05 October 2017	nca							21	<10	<10	14	<10	<10	<100	
VIS1	Vismodegib	The treatment of locally advanced or metastatic Basal Cell Carcinoma	29 July 2016	22 January 2018	<10	16	<10	<10	<10	13	13	15	11	26			<200	
					620	687	956	724	786	801	914	956	772	1173	1013	1139	10541	